I believe that Cherry, who essentially spent the e
Post# of 15624
(Total Views: 219)
Posted On: 03/30/2017 11:37:23 PM
I believe that Cherry, who essentially spent the entire day with the people from OWCP, did get the 20th from one or more of them. Why? Because this was no doubt a trial of limited and known duration.
I don't know precisely the requirements of the trial, but I can almost be certain that some minimum duration was established for observation of those being treated. Even after they added patients, they knew when the last patient was added, and they knew just how many days, weeks, or months the last patient entering the trial had to be observed for. Knowing that, they could know precisely what day the trial would end, at least they knew when they could unblind it and have a look. I suspect that was nearly the 20th, so that's why they were told to expect something then.
Remember, this trial was double blinded as I understand it. The decision to add more patients was probably made after a permitted peek, but once the last patient was added it wouldn't be unblinded until the last patient to enter was in the trial for the specified time. I believe they're still working on putting the data into a presentation suitable for peer review.
In other companies I've seen a limited amount of data included either in a quarterly report, or in a webcast associated with it. I don't know that they'll do a webcast, I hope so. If they do, questions are often limited to Analyst's who follow the company, and I suspect they have an indication of what they'll ask. Early in the life of some companies individual investors were permitted to ask questions as well, and I've had questions answered in some cases, and also been told that it was too early to discuss certain things in others. The Analyst's rarely asked questions that the company were unwilling to answer, but often the answers were rather evasive.
I've also been in companies where substantial income occurred after the quarter, or some fundraising had been done, while these figures weren't reported in the data, they were often discussed in the manuscript, which I believe is more important than the figures in the report.
Gary
I don't know precisely the requirements of the trial, but I can almost be certain that some minimum duration was established for observation of those being treated. Even after they added patients, they knew when the last patient was added, and they knew just how many days, weeks, or months the last patient entering the trial had to be observed for. Knowing that, they could know precisely what day the trial would end, at least they knew when they could unblind it and have a look. I suspect that was nearly the 20th, so that's why they were told to expect something then.
Remember, this trial was double blinded as I understand it. The decision to add more patients was probably made after a permitted peek, but once the last patient was added it wouldn't be unblinded until the last patient to enter was in the trial for the specified time. I believe they're still working on putting the data into a presentation suitable for peer review.
In other companies I've seen a limited amount of data included either in a quarterly report, or in a webcast associated with it. I don't know that they'll do a webcast, I hope so. If they do, questions are often limited to Analyst's who follow the company, and I suspect they have an indication of what they'll ask. Early in the life of some companies individual investors were permitted to ask questions as well, and I've had questions answered in some cases, and also been told that it was too early to discuss certain things in others. The Analyst's rarely asked questions that the company were unwilling to answer, but often the answers were rather evasive.
I've also been in companies where substantial income occurred after the quarter, or some fundraising had been done, while these figures weren't reported in the data, they were often discussed in the manuscript, which I believe is more important than the figures in the report.
Gary
(1)
(0)